Advice
ADVICE: following a full submission
imiquimod cream (Aldara®) is not recommended for use within NHS Scotland for the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adult patients when size or number of lesions limit the efficacy and/or acceptability of cryotherapy and other topical treatment options are contraindicated or less appropriate. Imiquimod cream was more effective than placebo in clearing actinic keratosis lesions.
However, the manufacturer did not provide a sufficiently robust economic analysis to gain acceptance by SMC. The licence holder has indicated their decision to resubmit.
Download detailed advice91KB (PDF)
Medicine details
- Medicine name:
- imiquimod 5% cream (Aldara)
- SMC ID:
- 385/07
- Indication:
- nonhyperkeratotic, nonhypertrophic actinic keratoses (AKs) on the face or scalp
- Pharmaceutical company
- Meda Pharmaceuticals Ltd
- BNF chapter
- Skin
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 09 July 2007